Medical/Pharmaceuticals
I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms
SHANGHAI and GAITHERSBURG, Md., July 9, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the signing of two new collaborations with emerging biote...
2021-07-09 20:00
30594
Sequanta and Mission Bio announce strategic partnership
SHANGHAI, July 8, 2021 /PRNewswire/ -- Sequanta Technologies Co., Ltd. ("Sequanta") and Mission Bio. ("Mission Bio") are pleased to announce that they have entered into a strategic partnership, providing high-quality single-cell sequence services using Mission Bio's products to customers in mainl...
2021-07-09 15:44
2373
Nippon Express (India) Newly Acquires GDP Certification at Three Locations
TOKYO, July 8, 2021 /PRNewswire/ -- Nippon Express (India) Private Limited (hereinafter "NE India"), a local subsidiary of Nippon Express Co., Ltd., obtained Good Distribution Practice (GDP) certification in April for its temperature-controlled hubs inDelhi, Mumbai and Ahmedabad, evidencing the ...
2021-07-08 15:00
1732
BioShin Expands Senior Leadership Team: Sarah Lu Joins BioShin as Chief Medical Officer, Mary Ma Joins BioShin as Chief Commercial Officer
SHANGHAI, July 8, 2021 /PRNewswire/ -- BioShin Limited today announced the appointment of Dr.Zhihong (Sarah) Lu as Chief Medical Officer and Dr. Ma (Mary) Li as Chief Commercial Officer. Sarah will play a critical role in BioShin's clinical development of pipeline products inAsia-Pacific markets,...
2021-07-08 12:01
2705
Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis
* Both batoclimab 340 mg and 680 mg treatment groups demonstrated rapid, substantial and persistent clinical improvement over placebo * Favorable safety and tolerability profile with no serious adverse events (SAEs) and no adverse events (AEs) leading to discontinuation * Strong IgG reductio...
2021-07-06 21:06
18668
Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD
ADELAIDE, Australia, July 6, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics or Company), a global, clinical stage biopharmaceutical company, is pleased to announce that it has initiated a Phase2b trial (the ATTUNE Study) to evaluate the tablet formulation of BNC210 in p...
2021-07-06 18:00
17848
Arctic Vision Joins Forces with the University of Hong Kong Department of Ophthalmology to Discover and Develop Novel Neuroprotective Therapies for Ocular Disease
SHANGHAI and HONG KONG, July 4, 2021 /PRNewswire/ -- Arctic Vision, a China -based clinical-stage ophthalmology company focuses on developing innovative therapies for pan-ocular diseases, announcing today a new research collaboration with Prof.Christopher Leung, Head and Clinical Professor at the ...
2021-07-05 08:00
2071
Transcenta Provides Program Update for Anti-Claudin18.2 Monoclonal Antibody TST001 and Reports Promising Early Anti-Tumor Responses in Patients with Gastric Cancer
SUZHOU, China, July 2, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announces that promising anti-tumor response...
2021-07-02 21:02
3202
First Naturally-designed and Personalised Bioprosthesis SingValve Set to Revolutionise Heart Valve Surgery
SINGAPORE, July 1, 2021 /PRNewswire/ -- A naturally-designed human-like personalised heart valve bioprosthesis developed by a team of clinician-scientists from theNational University Health System (NUHS) looks set to be a game changer in the next generation of "personalised medicine" and further...
2021-07-01 21:00
3414
Korea National Institute of Health (KNIH) conducts field inspection of companies with mRNA technology
SEOUL, South Korea, July 1, 2021 /PRNewswire/ -- Korea National Institute of
Health (KNIH), Korea's top research center in the field of hygiene and medicine
(with Mr. Kwon Jun-Wook as President) conducted a field inspection of key
companies with mRNA technology.
2021-07-01 21:00
2600
I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio
* First patient dosed in U.S. phase 1 clinical trial of TJ-CD4B/ABL111 in patients with advanced or metastatic solid tumors * China sites to join the dose expansion part of the study to accelerate TJ- CD4B/ABL111 development * Results of TJ-L14B/ABL503 preclinical studies accepted for publica...
2021-07-01 20:00
13740
Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson's
MELBOURNE, Australia and SAN FRANCISCO, July 1, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the granting of a new composition of matter patent by the United States Patent and Trademark Office (USPTO). The patent secures a ...
2021-07-01 19:50
14123
Joint Commission International publishes fourth edition of International Accreditation Standards for Laboratories
Standards and policies in latest edition become effective 1 January 2022 OAK BROOK, Ill., July 1, 2021 /PRNewswire/ -- Joint Commission International (JCI) today publishedJoint Commission International Accreditation Standards for Laboratories, Fourth Edition. The manual provides requirements for ...
2021-07-01 08:00
1815
Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs
SYDNEY, June 30, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801. Key Points * GBM AGILE pivotal study of paxalisib is...
2021-06-30 22:00
30944
VUNO Inks Deal with Samsung Electronics to Embed AI-powered Algorithms in Samsung's Premium Mobile X-ray System
SEOUL, South Korea, June 30, 2021 /PRNewswire/ -- South Korean artificial intelligence (AI) developer, VUNO Inc., announced today a partnership with Samsung Electronics Co., Ltd., global medical device company to incorporate its AI-powered chest X-ray diagnostic solution, VUNO Med®-Chest X-ray™, ...
2021-06-30 21:00
2215
I-Mab Honored with Top Rankings by Institutional Investor
SHANGHAI and GAITHERSBURG, Md., June 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it was ranked among the top companies by leading gl...
2021-06-30 20:00
13122
Akeso Awarded as 2021 "Most Honored Company" by Institutional Investor
HONG KONG, June 30, 2021 /PRNewswire/ -- Akeso, Inc. ("Akeso" or the "Company", stock code: 9926.HK) is pleased to announce today that, Akesohas been awarded as "Most Honored Company" in the "2021 All-Asia Executive Team" survey published byInstitutional Investor, and has been ranked top 3 in all...
2021-06-30 16:00
14030
OnCusp Therapeutics Commences Operations to Advance Innovative Oncology Therapies
NEW YORK, June 29, 2021 /PRNewswire/ -- OnCusp Therapeutics (or "OnCusp"), a global biopharmaceutical company focused on translating cutting-edge research assets into innovative oncology therapeutics, announced that it has officially commenced operations both inNew York and Shanghai. OnCusp succ...
2021-06-30 09:29
1906
Cynosure Celebrates 30 Years of Innovation
Aesthetics leader recognizes milestone with focus on future skin aesthetics innovation to help reveal the Beautiful Energy within everyone WESTFORD, Mass., June 29, 2021 /PRNewswire/ -- Since 1991, Cynosure has been a leader in the beauty aesthetics space, creating a comprehensive range of exper...
2021-06-29 21:00
2625
Hanmi Pharmaceutical finds new innovative potential for "Efpeglenatide"
SEOUL, South Korea, June 29, 2021 /PRNewswire/ -- Hanmi Pharmaceutical (hereinafter Hanmi) recently announced that its new, long-acting diabetes biologic drug, efpeglenatide, was shown to significantly reduce incidences of major adverse cardiovascular events (MACE) and kidney disease in the resul...
2021-06-29 21:00
3157
Week's Top Stories
Most Reposted
TotalEnergies ENEOS Extends Solar Partnership with Ceres in Indonesia
[Picked up by 316 media titles]
2026-06-08 10:16
DayOne Secures Over 1GW Renewable Energy in Malaysia in Landmark TNB Partnership
[Picked up by 303 media titles]
2026-06-04 23:55
Amartha Initiates Coalition to Advance Financial Health for Grassroots Communities in Indonesia
[Picked up by 296 media titles]
2026-06-05 19:08
DayOne Data Centers Announces Final Closing of its Series C Equity Financing at US$4.5 Billion
[Picked up by 294 media titles]
2026-06-05 15:00Omni HR Launches Mino, the First AI Agent Built on Unified APAC HR Data
[Picked up by 284 media titles]
2026-06-08 09:00
Most Read
YY Group (NASDAQ: YYGH) Wins Prestigious HAPA Solutions Excellence Award, Validating Enterprise AI Marketplace Adoption in Southeast Asia
2026-06-05 19:37
9568
Dreame ranked No.1 in Global Robot Vacuum Sales & Revenue, according to International Data Corporation (IDC)
2026-06-05 21:05
8345
Tuniu Announces Unaudited First Quarter 2026 Financial Results
2026-06-05 18:00
8289
Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval
2026-06-05 22:00
7917
NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
2026-06-05 21:13
7674
